Work

P06 | From Bench to Bedside: Drug Sensitivity Profiling to Optimize Therapy in Relapsed Multiple Myeloma

Year: 2026

Type: article

Abstract: Introduction. Relapsed multiple myeloma (MM) is a genetically heterogeneous malignancy characterized by variable responses to therapy in later lines of treatment. Despite the availability of highly effective agents, most patients eventually relapse and require additional therapeutic options. Precision medicine is increasingly important in this setting; however, the lack of robust predictive biomarkers limits individualized treatment selection. We evaluated a novel high-throughput drug sensitivity assay (clinicaltrials.gov NCT03389347) to predict treatment responses in relapsed/refractory MM.Methods. Eligible patients had MM or plasma cell leukemia with relapsed/refractory disease, ≥3 prior lines of therapy (LOT) including an IMiD and a proteasome inhibitor (PI),

Source: Haematologica

DOI: 10.3324/haematol.2026.s2.14100